Testosterone

To study the accumulation and biodistribution of FDHT in patients with progressive prostate cancer. The accumulation and location of FDHT activity will be assessed on a site by site basis and correlated with radionuclide bone scan, CT and MRI.

Comparison of hair cortisol and testosterone levels between the patients with acute MI and the 2 control groups

Number of oocytes retrieved

Depressive Symptom Severity

Change in headache burden

patient and spouse satisfaction an quality of life

Change From Baseline on the Delis-Kaplan Executive Function System

PSA-concentration

Number of days required for a patient to be recruited on the study and how many patients are recruited

Waist Circumference

Fiber cross-sectional area

differences in serum lipid levels

Progression in the development of secondary sexual characteristics

Lean Body Mass

Thigh Cross Sectional Area

Percentage of Patients Completing at Least 3 Months of Therapy With a PSA Below Baseline.

Total score in the Treatment Satisfaction Questionnaire for Medication (TSQM)

Salivary testosterone concentration

Testosterone influence on Insulin Sensitivity, Lipolysis and protein metabolism

Androgen receptor

Time to Event, Defined as ≥ 50% Loss of Strength in the Hip Flexors as Assessed by Dynamometry Peak Force Measures at Baseline and at 1, 3, 5, and 7 Months

Gleason grade progression

Change From Baseline in Common Carotid Artery Intima-Media Thickness (IMT)

Change from baseline in fat-free mass, measured by DEXA scanning

Number of participants with changes in 24-hour average systolic ambulatory blood pressure

Bone density and strength

Insulin Sensitivity

Effects of testosterone enanthate and testosterone gel on BMI, haemoglobin, haematocrit, urea creatinine, triglyceride, total testosterone (TT) and HDL-cholesterol were measured.

blood-to-brain clearance/trapping (K*) of [11C]AMT

Fat-Free Mass (kg)

Evidence of Luteal Activity (ELA)

Change in Body Fat Percentage

Effects of testosterone replacement therapy on glycemic control - fasting plasma glucose (FPG) mmol/l

Body Composition at the End of Each Study Phase

the effect of testosteron replacement treatment on the Fibroblast Growth Factor-23.

Effect of Androgel Treatment on Relative Nuclear Factor kB Activity Compared to Placebo

Restricted Functional Independence Measure (FIM)

Response of treatment for 4 injections at 1 year; score on an IIEF-5

The effect of testosterone replacement on arterial stiffness measured by ultrasound derived index B of the femoral artery in men with a combination of DM, PVD and hypogonadism.

Change in insulin sensitivity as measured by HOMA-IR

Baseline (Pre-ibutilide) Individualized Rate-corrected QT Interval (QTF)

Steroid Levels in Urine Steroid Profile

Evidence of Luteal Activity (ELA)

Sexual Function Trial - Change in Psychosexual Daily Questionnaire Question 4 (PDQ-Q4) From Baseline to Month 12

To assess the efficacy of testosterone transdermal system (TS) as measured by the change from baseline in the frequency of total satisfying sexual activity captured by the Sexual Activity Log (SAL).

Lean body mass at 6 months

Percentage of Treated Patients With Average Serum Testosterone (T) Concentrations (Cavg) Between 300 and 1000 ng/dL

Serum Testosterone Cavg

Clinical pregnancy

waist-to-hip ratio

Change in Item #3 (Average) of the Brief Pain Inventory (BPI) Average Pain From Baseline to Month 3

The Percentage of Subjects on Day 90 Whose Cavg (0-24) Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL

Insulin sensitivity,

The Percentage of Subjects Whose Average Concentration (Cave(0-24)) Serum Total Testosterone Levels Are ≥300 and ≤1050 ng/dL

Overall mood

Percentage of Participants Meeting Serum Total Testosterone Average Concentration (Cavg) Criteria at Day 90

Percentage of Treated Patients With an Average Serum Testosterone (T) Concentration (Cavg) Between 300 and 1000 ng/dL

Evaluate hormonal, metabolic thromboembolic and clinical effects on climacteric symptoms

Comparison of the proportion of subjects who meet the composite endpoint of normal 24-hour average testosterone and sperm concentration.

Efficacy and Safety of long term treatment with TU under real-life conditions

Change in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DXA)

Change in the Physical Performance Test

Change From Baseline MTE08 to MTE09 Endpoint in Draize Score

Change in semen volume from baseline and between the treatment arms

Stand-up-and Sit-test

Prostate Tissue DHT Concentrations After Treatment

Nodule Size per Number

Fat-free mass

Typical pain with vaginal penetration within last 2 weeks

Change in MRI Cross Sectional Area of the Quadriceps

Mean change in frequency of moderate to severe vasomotor symptoms (VMS) from baseline to Week 4

Change from baseline on the total score of the AMS rating scale

In patients with chronic heart failure, does 26 weeks of treatment with transdermal testosterone improve peak VO2?

Progression Free Survival as Measured by Number of Months Until Clinical or Radiographic Progression

Satisfactory Sexual Episodes

The number of satisfactory sexual encounters based on event questionnaires on active drug as compared to placebo during double-blind treatment period episodes in the domestic setting.

Changes in scores in the Pain Interference Subscale of the Brief Pain Inventory (BPI) questionnaire

Clinical or Radiographic Progression free survival

Changes in sexual disorders measured by FSFI (Female Sexual Function index) after 12 and 24 weeks of treatment

measures of fractional synthetic rates of mixed and contractile (actin and myosin heavy chain [MHC]) skeletal muscle proteins and degradation of skeletal muscle (ubiquitin, and proteasome sub-units)

weight

Transference of Topical Testosterone from Dosed Males to Female Partners As Measured by net change from Baseline of Serum Testosterone in nG/dL expressed as Maximum Serum Concentration or Cmax.

Brief Pain Inventory (BPI) at Week 14

Change From Baseline in VO2 Peak (L/Min) Achieved During Arm Ergometry Exercise Alone

The primary endpoint is the number of satisfactory sexual episodes, measured using the Sexual Satisfaction of an Event Questionnaire (SSEQ).

Change From Baseline in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Ejaculatory Function Score at 16 Weeks

female sexual function index score

Stair climb

6-month radiographic progression-free survival (rPFS)

Prostate (size, PSA-level)

PSA response

PSA response rate at Cycle 1 Day 64

Aerobic performance

Dose Range Measure of serum levels of testosterone in response to varying doses

Percent Change in Spine Bone Density From Baseline to 12 Months

Effect of Testosterone Gel vs. Anastrozole on Bone Mineral Density

Percent of Subjects With Testosterone Levels in the Normal Range.

Pain Interference Subscale score of the Brief Pain Inventory (BPI) questionnaire

Patients With PSA <4 ng/mL at the End of the Study

Endothelial Progenitor Cells

Testosterone

PSA Response Rate

Pourcentage of patients with normal median value of serum total testosterone

Serum Testosterone Average Concentration (Cavg) (ng/dL)

Myocardial Perfusion

Cmax of Serum Testosterone

change in thigh muscle cross-sectional area

Responder Rate - the Percentage of Subjects Whose Minimum Concentration Observed (Cmin) and Average Steady State Concentration (Cave) of Serum Testosterone Levels Were Between 298 and 1043 ng/dL.

Mean T Cavg25 Following Meals Containing Various Amounts of Dietary Fat Compared to Normal Fat Diet

Serum T Concentration at Steady State

Mean Serum Testosterone Cavg

Treatment effects and correlation of changes in morphometrics and biomarkers as assessed by mammogram and magnetic resonance image (MRI) densities on days 1 and 300

Effect of testosterone on QLQ C-30 score

Change in fatigue (measured with Modified Fatigue Impact Scale [M-FIS])

Clinical and Ongoing Pregnancy

Adverse Events

Intratesticular hormone levels

Dutasteride can suppress the secretion of LH and FSH after four weeks of administration.

Number of Participants Demonstrating Abstinence

Serum Testosterone (Total)

average serum testosterone after dosing on day 2

% of Mean Difference in T Concentration Compared to Plain Collection Tube

Short Physical Performance Battery- Gait, Balance, Chair Rise changes in functional measure score

Percent Change in Bone Mineral Density (BMD) According to rs700518 Polymorphism in the CYP19A1 Gene

Physical Performance

penile curvature

Gonadotropin Suppression

LH and Testosterone levels will be evaluated after 4 study visits

Pharmacokinetics: Area Under the Concentration Curve (AUC) of Testosterone

Change in Total Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DEXA) From Baseline to 7 Weeks.

Testosterone serum concentrations - Peak Plasma Concentration (Cmax)

Change in dosage of Erythropoietin stimulating agents (ESA)

Change from Baseline in muscle derived protein synthesis rate

To measure the amount of testosterone in the blood after dosing

Androgen receptor (AR) activity

Maximum Testosterone Concentration

The amount of Testerone MD-Lotion 2% remaining on the axilla after a single dose application in healthy males who undergo a post dose washing procedure.

Maximum plasma concentration (Cmax)

Change in steroid profile in urine

Prostate-specific Antigen (PSA) Response

increase in standardize uptake values (SUV) between the second and third FDHT scans

Feasibility of the Administration of Transdermal Testosterone Alternating with Enzalutamide

Baroreflex Response to LBNP

Pain Tolerance

Total Female Sexual Function Index (FSFI) Score

Change in Fat-free Mass as Measured by Bioelectric Impediance Analysis (BIA)